Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review
Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer. A comprehensive search was performed on PubMe...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2022-01, Vol.36 (1), p.40-48 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 48 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | In vivo (Athens) |
| container_volume | 36 |
| creator | Serban, Dragos Costea, Daniel Ovidiu Zgura, Anca Tudosie, Mihail Silviu Dascalu, Ana Maria Gangura, Gabriel Andrei Smarandache, Catalin Gabriel Dan Sabau, Alexandru Tudor, Corneliu Faur, Mihai Costea, Andreea Cristina Stana, Daniela Balasescu, Simona Andreea Tribus, Laura Carina Tanasescu, Ciprian |
| description | Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
A comprehensive search was performed on PubMed, Web of Science and Google scholar.
After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment. |
| doi_str_mv | 10.21873/INVIVO.12674 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8765131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2615922696</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-e8d3811636f638de28c5b8febc3dce9a5c5cc1f53c5cc53aa72c431bcc2a60b83</originalsourceid><addsrcrecordid>eNpVkUtPwzAQhC0EgvI4ckU-ckmJ7fqRC1KpClRCVIJScbMcZ0ONUrvYaRH_nvAUnOaw386uZhA6JnmfEiXZ2eR2PplP-4QKOdhCPSILkkk-KLZRL6dcZYqTxz20n9JznguZ53QX7bFBIakoVA89Tu26MRHfuwrwuK7BtgmHGg9jWJrWJMATv3Cla0PEY18FG50HPFtANKs37Dy-iGBSi0fGW4g4w0N8BxsHr4dopzZNgqNvPUAPl-PZ6Dq7mV5NRsObzDIl2wxUxRQhgolaMFUBVZaXqobSsspCYbjl1pKasw_lzBhJ7YCR0lpqRF4qdoDOv3xX63IJ3Y5vo2n0KrqliW86GKf_T7xb6Kew0UoKThjpDE6_DWJ4WUNq9dIlC01jPIR10lQQXtAuLdGh2RdqY0gpQv17huT6sw3t_MZtgv5so-NP_v72S__Ez94BgoSH8w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615922696</pqid></control><display><type>article</type><title>Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Serban, Dragos ; Costea, Daniel Ovidiu ; Zgura, Anca ; Tudosie, Mihail Silviu ; Dascalu, Ana Maria ; Gangura, Gabriel Andrei ; Smarandache, Catalin Gabriel ; Dan Sabau, Alexandru ; Tudor, Corneliu ; Faur, Mihai ; Costea, Andreea Cristina ; Stana, Daniela ; Balasescu, Simona Andreea ; Tribus, Laura Carina ; Tanasescu, Ciprian</creator><creatorcontrib>Serban, Dragos ; Costea, Daniel Ovidiu ; Zgura, Anca ; Tudosie, Mihail Silviu ; Dascalu, Ana Maria ; Gangura, Gabriel Andrei ; Smarandache, Catalin Gabriel ; Dan Sabau, Alexandru ; Tudor, Corneliu ; Faur, Mihai ; Costea, Andreea Cristina ; Stana, Daniela ; Balasescu, Simona Andreea ; Tribus, Laura Carina ; Tanasescu, Ciprian</creatorcontrib><description>Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
A comprehensive search was performed on PubMed, Web of Science and Google scholar.
After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>DOI: 10.21873/INVIVO.12674</identifier><identifier>PMID: 34972698</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Antineoplastic Agents, Hormonal - adverse effects ; Aromatase Inhibitors - adverse effects ; Breast Neoplasms - drug therapy ; Female ; Humans ; Review</subject><ispartof>In vivo (Athens), 2022-01, Vol.36 (1), p.40-48</ispartof><rights>Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright 2022, International Institute of Anticancer Research 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-e8d3811636f638de28c5b8febc3dce9a5c5cc1f53c5cc53aa72c431bcc2a60b83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765131/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765131/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34972698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serban, Dragos</creatorcontrib><creatorcontrib>Costea, Daniel Ovidiu</creatorcontrib><creatorcontrib>Zgura, Anca</creatorcontrib><creatorcontrib>Tudosie, Mihail Silviu</creatorcontrib><creatorcontrib>Dascalu, Ana Maria</creatorcontrib><creatorcontrib>Gangura, Gabriel Andrei</creatorcontrib><creatorcontrib>Smarandache, Catalin Gabriel</creatorcontrib><creatorcontrib>Dan Sabau, Alexandru</creatorcontrib><creatorcontrib>Tudor, Corneliu</creatorcontrib><creatorcontrib>Faur, Mihai</creatorcontrib><creatorcontrib>Costea, Andreea Cristina</creatorcontrib><creatorcontrib>Stana, Daniela</creatorcontrib><creatorcontrib>Balasescu, Simona Andreea</creatorcontrib><creatorcontrib>Tribus, Laura Carina</creatorcontrib><creatorcontrib>Tanasescu, Ciprian</creatorcontrib><title>Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
A comprehensive search was performed on PubMed, Web of Science and Google scholar.
After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.</description><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Aromatase Inhibitors - adverse effects</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Review</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtPwzAQhC0EgvI4ckU-ckmJ7fqRC1KpClRCVIJScbMcZ0ONUrvYaRH_nvAUnOaw386uZhA6JnmfEiXZ2eR2PplP-4QKOdhCPSILkkk-KLZRL6dcZYqTxz20n9JznguZ53QX7bFBIakoVA89Tu26MRHfuwrwuK7BtgmHGg9jWJrWJMATv3Cla0PEY18FG50HPFtANKs37Dy-iGBSi0fGW4g4w0N8BxsHr4dopzZNgqNvPUAPl-PZ6Dq7mV5NRsObzDIl2wxUxRQhgolaMFUBVZaXqobSsspCYbjl1pKasw_lzBhJ7YCR0lpqRF4qdoDOv3xX63IJ3Y5vo2n0KrqliW86GKf_T7xb6Kew0UoKThjpDE6_DWJ4WUNq9dIlC01jPIR10lQQXtAuLdGh2RdqY0gpQv17huT6sw3t_MZtgv5so-NP_v72S__Ez94BgoSH8w</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Serban, Dragos</creator><creator>Costea, Daniel Ovidiu</creator><creator>Zgura, Anca</creator><creator>Tudosie, Mihail Silviu</creator><creator>Dascalu, Ana Maria</creator><creator>Gangura, Gabriel Andrei</creator><creator>Smarandache, Catalin Gabriel</creator><creator>Dan Sabau, Alexandru</creator><creator>Tudor, Corneliu</creator><creator>Faur, Mihai</creator><creator>Costea, Andreea Cristina</creator><creator>Stana, Daniela</creator><creator>Balasescu, Simona Andreea</creator><creator>Tribus, Laura Carina</creator><creator>Tanasescu, Ciprian</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review</title><author>Serban, Dragos ; Costea, Daniel Ovidiu ; Zgura, Anca ; Tudosie, Mihail Silviu ; Dascalu, Ana Maria ; Gangura, Gabriel Andrei ; Smarandache, Catalin Gabriel ; Dan Sabau, Alexandru ; Tudor, Corneliu ; Faur, Mihai ; Costea, Andreea Cristina ; Stana, Daniela ; Balasescu, Simona Andreea ; Tribus, Laura Carina ; Tanasescu, Ciprian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-e8d3811636f638de28c5b8febc3dce9a5c5cc1f53c5cc53aa72c431bcc2a60b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Aromatase Inhibitors - adverse effects</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serban, Dragos</creatorcontrib><creatorcontrib>Costea, Daniel Ovidiu</creatorcontrib><creatorcontrib>Zgura, Anca</creatorcontrib><creatorcontrib>Tudosie, Mihail Silviu</creatorcontrib><creatorcontrib>Dascalu, Ana Maria</creatorcontrib><creatorcontrib>Gangura, Gabriel Andrei</creatorcontrib><creatorcontrib>Smarandache, Catalin Gabriel</creatorcontrib><creatorcontrib>Dan Sabau, Alexandru</creatorcontrib><creatorcontrib>Tudor, Corneliu</creatorcontrib><creatorcontrib>Faur, Mihai</creatorcontrib><creatorcontrib>Costea, Andreea Cristina</creatorcontrib><creatorcontrib>Stana, Daniela</creatorcontrib><creatorcontrib>Balasescu, Simona Andreea</creatorcontrib><creatorcontrib>Tribus, Laura Carina</creatorcontrib><creatorcontrib>Tanasescu, Ciprian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serban, Dragos</au><au>Costea, Daniel Ovidiu</au><au>Zgura, Anca</au><au>Tudosie, Mihail Silviu</au><au>Dascalu, Ana Maria</au><au>Gangura, Gabriel Andrei</au><au>Smarandache, Catalin Gabriel</au><au>Dan Sabau, Alexandru</au><au>Tudor, Corneliu</au><au>Faur, Mihai</au><au>Costea, Andreea Cristina</au><au>Stana, Daniela</au><au>Balasescu, Simona Andreea</au><au>Tribus, Laura Carina</au><au>Tanasescu, Ciprian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>36</volume><issue>1</issue><spage>40</spage><epage>48</epage><pages>40-48</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
A comprehensive search was performed on PubMed, Web of Science and Google scholar.
After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>34972698</pmid><doi>10.21873/INVIVO.12674</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2022-01, Vol.36 (1), p.40-48 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8765131 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antineoplastic Agents, Hormonal - adverse effects Aromatase Inhibitors - adverse effects Breast Neoplasms - drug therapy Female Humans Review |
| title | Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T12%3A46%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20Side%20Effects%20of%20Aromatase%20Inhibitor%20Endocrine%20Therapy%20in%20Breast%20Cancer%20-%20A%20Review&rft.jtitle=In%20vivo%20(Athens)&rft.au=Serban,%20Dragos&rft.date=2022-01-01&rft.volume=36&rft.issue=1&rft.spage=40&rft.epage=48&rft.pages=40-48&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/10.21873/INVIVO.12674&rft_dat=%3Cproquest_pubme%3E2615922696%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2615922696&rft_id=info:pmid/34972698&rfr_iscdi=true |